Research as of June 11, 2026. Short interest: FINRA settlement May 29, 2026. Borrow rates: Interactive Brokers live. Re-run research periodically for fresh short interest levels.
WOLFWolfspeed, Inc.
HIGH RISK
Short % Float
54.5%
Days to Cover
2.8
Borrow Rate
~6.6% (peak 932%)
Catalyst
Q4 FY2026 earnings
Aug 19, 2026
📋 Catalyst Detail
Post-Ch.11 bankruptcy emergence (Sept 2025); 70% debt cut; pivoting to SiC silicon for AI/HPC data centers. Renesas equity investment finalized post-CFIUS. Ultra-thin post-bankruptcy float (~48M shares).
📈 Entry Strategy
Long shares or slightly OTM Aug/Sep calls ahead of Aug 19 earnings. Watch for pre-announcement of SiC data-center supply agreements as secondary trigger. 54% float short on a thin post-bankruptcy float = limited cover capacity.
⚠️ Failed Squeeze Risk
Negative gross margins persist; ongoing cash burn. Stock already up 273% YTD — conviction shorts may hold firm. Post-bankruptcy equity dilution ongoing. Q4 guidance miss collapses the SiC/AI narrative entirely.
AI-native rebrand announced May 21, 2026; ~400 job cuts; $20–25M annual savings target; Investor Day planned H2 2026. Only ~24M share float with 52% short.
📈 Entry Strategy
Long shares or calls ahead of earnings. Any concrete AI-agent revenue announcement is a secondary trigger. Tapeboard squeeze composite score: 51.
⚠️ Failed Squeeze Risk
Core local-deals business in secular decline; AI pivot is marketing-stage not revenue-stage. Q2 miss leaves the bear thesis fully intact. Borrow only 1.15% — no carry urgency.
FY2026 guidance: $225–260M revenue (+33–54% YoY). Over 75% of customers migrating to Agentic 7.3 by mid-2026. Automotive OEM infotainment design wins ongoing. Shorts collectively paying ~$128M/year in carry at 9.55%.
📈 Entry Strategy
Long shares or Sep calls. High carry cost (~$128M/yr collective) creates mechanical pressure. Any Q2 beat or major partnership announcement triggers cascade. Watch auto show / AI conference news.
⚠️ Failed Squeeze Risk
Persistent net losses and high SBC. Premium valuation vs. actual revenue. If Q2 misses or Agentic 7.3 migration delays, the 'overvalued AI hype' bear case prevails. Prior 38% short levels did not produce a full squeeze.
Phase 3 HAELO data (87% reduction in HAE attack rates; 62% attack-free) presented at EAACI Congress, Jun 12–15, 2026 (Istanbul). Rolling BLA completion targeted H2 2026; U.S. launch H1 2027. $180M equity raise (April) provides runway to PDUFA.
📈 Entry Strategy
9.2-day DTC forces extended covering once triggered. EAACI data is a near-term binary event. Long shares or Jul/Aug calls. AdCom scheduling announcement = mid-road secondary catalyst.
⚠️ Failed Squeeze Risk
$180M offering caused ~15% stock drop on dilution. FDA cautious extrapolating Chinese-trial CRISPR data to U.S. populations. Competition from Alnylam ALHEMO and other HAE therapies. Rolling BLA timelines can slip; CRL risk is real.
Q1 2026: revenue $308M (+44% YoY), originations +61% YoY. FY2026 guidance: ~$1.4B revenue, ~$294M adj. EBITDA. Short interest rising (+3.63% last period) as bears remain skeptical.
📈 Entry Strategy
Q2 beat with raised guidance forces rapid covering given 5.8 DTC. Long shares or Aug calls. Improving macro (rate cuts) amplifies bull case as origination volumes surge and default risk eases.
⚠️ Failed Squeeze Risk
Borrow only 0.37% — shorts have no carry urgency; new entries freely available. Model unproven through full credit downturn. If Congress passes rate caps on personal loans, TAM collapses overnight. Fundamentals-driven, not mechanically forced.
Gravity SUV named 2026 World Luxury Car of the Year. Nuro robotaxi partnership: production validation Q3, commercial launch late 2026. 2026 production guidance: 25,000–27,000 vehicles. Saudi PIF backstop. Only ~20K IB shares available to borrow at 22.82%.
📈 Entry Strategy
22.8% borrow rate + only ~20K IB shares = hardest-to-borrow EV name on list. Monthly delivery/production reports are discrete catalysts. Long shares or Jul/Aug calls. Monitor delivery reports as interim triggers.
⚠️ Failed Squeeze Risk
Missed Q1 2026 with $1B net loss; WITHDREW 2026 production guidance. Cash burn ~$1.95B/year, entirely PIF-dependent. Nuro robotaxi delays are common. Saudi geopolitical risk is real.
First-in-class PD-1 + VEGF bispecific for EGFRm NSCLC post-TKI. Phase III HARMONi trial. Short interest surged +21.16% in one period. ~14,000 eligible U.S. patients/year. AdCom scheduling = mid-road catalyst.
📈 Entry Strategy
8.2 DTC + binary PDUFA event. Jan 2027 calls to bridge the approval date. AdCom scheduling announcement is a pre-PDUFA secondary catalyst. Short interest surged 21% in one period — crowded short heading into binary.
⚠️ Failed Squeeze Risk
Pivotal data from Chinese population (HARMONi) — FDA cautious extrapolating to U.S. populations; CRL risk is substantial. A rejection could wipe 50–70% of value. Borrow 0.43% — shorts enter freely with no urgency.
Q1 2026 blowout: revenue $1.85B (+26.7% YoY), adj. EPS $0.43 vs $0.27 est.; stock +73%. Short interest jumped +20.36% as bears bet on mean reversion. Activist investor Starteepo Invest discloses 5.05% stake. ⚠️ Warning: Q2 may have already shown EPS miss — verify before entry.
📈 Entry Strategy
Bears shorted the Q1 rally hard — crowded short into Q2. Activist stake creates potential for buyback / asset sale announcement. Limited borrow supply (100K IB shares at 4.5%) adds mechanical pressure. Long ahead of Jul 28 — VERIFY Q2 results are not already out first.
⚠️ Failed Squeeze Risk
⚠️ Q2 may have already reported an EPS miss (-$0.64 vs +$0.07 est.). Squeeze window may have opened and closed. Core printing business in terminal secular decline. Q1 revenue boost possibly one-time from HPA acquisition.
Q2 guidance: revenue $59–65M (midpoint +12% sequential). $25M radar production order from Tier-1 auto partner for two OEMs. Strategic backlog: $7.4B. ADAS radar/vision processor ramp underway.
📈 Entry Strategy
9.2 DTC is among the longest on this list — once triggered, covering is extended. $25M radar order validates the ADAS thesis. Long shares or Sep calls. Watch for additional OEM design-win announcements.
⚠️ Failed Squeeze Risk
Unprofitable (operating loss $11.1M Q1). Competing against Mobileye, NXP, TI — subscale in ADAS. Auto semiconductor demand faces global tariff disruption. Wuxi acquisition integration risk. Q2 miss could push short interest higher.
CB4/CB5 data center lease commencements targeted Q3/Q4 2026. $21M HPC leasing revenue in Q1 (first major contribution). 60MW energized at Lake Mariner. Pivot: Bitcoin mining → HPC/AI hosting.
📈 Entry Strategy
Each CB4/CB5 commencement is a discrete press-release catalyst ahead of earnings. 108M shares short in absolute terms = large covering demand if thesis validates. Enter ahead of expected Q3 commencement news.
⚠️ Failed Squeeze Risk
Borrow only 0.5% — no mechanical urgency for shorts. BTC price dependency in legacy mining segment. CB4/CB5 tenants could delay or cancel. Squeeze requires fundamental validation, not technical forced-covering.
Uber robotaxi partnership: Lucid vehicles + Nuro self-driving in SF Bay Area; commercial launch targeted late 2026. Oro Mobility autonomous fleet launched. Q1 2026: revenue +11% YoY, RPD +5.5% YoY. ⚠️ Note: 18.37% float is slightly below the 20% threshold.
📈 Entry Strategy
8.1 DTC is high; Uber/Nuro robotaxi catalyst is concrete and near-term. Stock demonstrated 85%+ squeeze earlier in 2026. Long shares or Nov calls to capture the robotaxi launch narrative.
⚠️ Failed Squeeze Risk
Second post-bankruptcy cycle — history of capital destruction. Robotaxi tech delays are common; Nuro partnership unproven at scale. Fleet value risk from EV depreciation. Borrow easy (0.7%) — no short urgency.
VS-7375-101 early clinical data readout due H1 2026. First patients in TARGET-D 201/202/203 trials mid-2026. FDA-approved AVMAPKI FAKZYNJA commercially launched. Short interest grew from 0.7% to 24.6% in just 12 months.
📈 Entry Strategy
10.1 DTC is the longest on this list — covering once triggered is the most extended process. Short position grew from near-zero to 24.6% on a newly commercial biotech. Long shares before H1 2026 VS-7375 data. Small float amplifies any move.
⚠️ Failed Squeeze Risk
AVMAPKI approved under accelerated approval — full approval requires RAMP 301 confirmatory data not until mid-2027. RAMP 301 failure revokes approval. Commercial revenues modest ($17.5M/quarter). Borrow 0.31% — no carry urgency.
~18.8M share float with ~39% short per Tapeboard. Fed rate cuts directly stimulate high-end housing purchases. International expansion (RH England, RH France) is a revenue diversification story.
📈 Entry Strategy
Thin float + 39% short = very limited cover capacity. Any positive housing sentiment or above-expectations comp triggers cascade. Long shares or calls ahead of rate decisions or quarterly earnings.
⚠️ Failed Squeeze Risk
RH down ~50% over trailing year — shorts have been right. Revenue declining as housing turnover froze. If rates stay elevated longer, recovery timeline slips further. CEO execution inconsistent. Borrow 0.4%.
Dominant global webcomic platform (160M+ monthly users). Q1 2026: revenue ~$321M, EBITDA above guidance. Potential M&A interest from media/entertainment conglomerates. ⚠️ Note: DTC and borrow rate not separately confirmed; Finviz screener data only.
📈 Entry Strategy
Platform scale (160M users) + improving EBITDA + M&A premium could catch bears off guard. Enter lightly given data gaps. Watch for M&A speculation headlines or strong earnings beat.
⚠️ Failed Squeeze Risk
Weakest data confirmation on this list — DTC and borrow unconfirmed. Persistent net losses. Competition from manga streaming and TikTok short-form. Treat as speculative addition only.
114% short of float per Tapeboard — more shares short than exist in public float. 1-for-10 reverse stock split enacted Jun 8, 2026. ~$35M market cap post-split. EPS est. -$0.17 for Q3. iBuying re-rating if housing rates ease.
📈 Entry Strategy
Pure mechanics: 114% short float means every covering transaction competes for shares that don't fully exist. Even small buying volume creates outsized price moves. MUST use tiny position sizes — lottery ticket, not a core holding. Aug 3 earnings + housing-positive macro print could ignite.
⚠️ Failed Squeeze Risk
Near-distressed microcap on reverse-split watch. iBuying carries massive inventory risk. Consensus expects another loss quarter. The 114% figure may reflect stale post-split float data. Stock could delist or dilute before a squeeze materializes. HIGHEST risk/reward name on this list.